Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Going Public

Direct-to-consumer genetic testing company 23andMe is merging with VG Acquisition Corp. with the aim of becoming publicly traded, as GenomeWeb reports. It notes VG Acquisition Corp. is a special-purpose acquisition company (SPAC) sponsored by Virgin Group.

The Verge adds that SPACs, in which a group of investors form a company with the aim of taking another one over, have recently become more popular. It notes that this deal between 23andMe and VG Acquisition Corp values the company at $3.5 billion and that current shareholders will own 81 percent of the company.

According to the Wall Street Journal, the deal would also enable 23andMe to shift away from the consumer DNA testing market — which it notes has been slowing — toward a health market. "There is absolutely that slowdown," 23andMe CEO Anne Wojcicki tells the Journal. "We have always seen health as a much bigger opportunity."

GenomeWeb adds that the transaction is expected to be completed during the second quarter and that the combined company's shares will be traded under the 'ME' ticker symbol.



The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.